Kyntra Bio Inc

KYNB Healthcare Biotechnology

In the quarter to June 2026, revenue fell 209.4%, EPS grew 257.5% and free cash flow fell 131.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

4.85 0.51 −9.51%
Market cap
$21.7M
P/E
0.1×
Fwd P/E
−0.5×
Dividend yield
—
F-score
5/9
Altman Z
−20.33
Beneish M
−4.57
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
5 5 5 —

+8 more TTM periods

ROE
(157.83%) (144.04%) (165.18%) (189.86%)
ROA
131.26% 119.06% 109.81% 107.44%
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
301.38% 223.39% 262.71% 221.30%
Average Days of Receivables
27.43 247.29 12.24 5.32
Free Cash Flow per Share
(9.40) (5.28) (1.19) (4.18)
Free Cash Flow
(38.05) (21.38) (4.81) (16.88)
Other line items

Show all line items

Columns are period end dates